Literature DB >> 7398754

Prenatal and neonatal drug metabolism in man.

A Rane, G Tomson.   

Abstract

Drug oxidations are catalyzed by the liver microsomal fraction of human fetuses but not by fetal livers from most experimental animals. In contrast, glucuronidation of some substrates is catalyzed by the rat fetal liver in late gestation but not in the human fetal liver. The deficient human fetal glucuronidation seems to be compensated for by early development of sulfation activity. The inconsistency of the results from animal fetuses and human fetuses shows that animal data have little relevance for the human fetus. No generalized statements can be made about drug disposition in the newborn infant as compared to adults. Although most drugs that are oxidized have prolonged plasma half-lives in the neonatal period there are examples of drugs with half-lives similar to, or even shorter than, the average half-lives in adults. Oxazepam is conjugated with glucuronic acid in adults. The neonatal plasma half-life of this drug is considerably prolonged. This is true also for its conjugate as would be expected from the immature renal function in newborns. Adequate pharmacokinetic information is a prerequisite for rational and safe drug treatment in the neonatal period.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7398754     DOI: 10.1007/bf00561473

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  41 in total

1.  Paracetamol metabolism following overdosage: application of high performance liquid chromatography.

Authors:  D Howie; P I Adriaenssens; L F Prescott
Journal:  J Pharm Pharmacol       Date:  1977-04       Impact factor: 3.765

2.  Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses.

Authors:  C F WEISS; A J GLAZKO; J K WESTON
Journal:  N Engl J Med       Date:  1960-04-21       Impact factor: 91.245

3.  Acetaminophen-induced hepatic necrosis. I. Role of drug metabolism.

Authors:  J R Mitchell; D J Jollow; W Z Potter; D C Davis; J R Gillette; B B Brodie
Journal:  J Pharmacol Exp Ther       Date:  1973-10       Impact factor: 4.030

4.  Perinatal development of drug-metabolizing enzyme activity in swine.

Authors:  C R Short; L E Davis
Journal:  J Pharmacol Exp Ther       Date:  1970-08       Impact factor: 4.030

5.  Fetal hepatic drug metabolism in the nonhuman primate, Macaca arctoides.

Authors:  B H Dvorchik; B G Stenger; S L Quattropani
Journal:  Drug Metab Dispos       Date:  1974 Nov-Dec       Impact factor: 3.922

6.  Disposition of meperidine in pregnancy.

Authors:  D Morgan; G Moore; J Thomas; E Triggs
Journal:  Clin Pharmacol Ther       Date:  1978-03       Impact factor: 6.875

7.  Studies on glucoronide formation in newborn infants and older children. Measurement of paminophenol glucuronide levels in the serum after an oral dose of acetanilid.

Authors:  M F VEST; R R STREIFF
Journal:  AMA J Dis Child       Date:  1959-12

8.  Meperidine and normeperidine levels following meperidine administration during labor. I. Mother.

Authors:  B R Kuhnert; P M Kuhnert; A S Tu; D C Lin; R L Foltz
Journal:  Am J Obstet Gynecol       Date:  1979-04-15       Impact factor: 8.661

9.  Meperidine and normeperidine levels following meperidine administration during labor. II. Fetus and neonate.

Authors:  B R Kuhnert; P M Kuhnert; A S Tu; D C Lin
Journal:  Am J Obstet Gynecol       Date:  1979-04-15       Impact factor: 8.661

10.  Amniotic fluid transfer of meperidine from maternal plasma in early pregnancy.

Authors:  H H Szeto; I A Zervoudakis; L L Cederqvist; C E Inturrisi
Journal:  Obstet Gynecol       Date:  1978-07       Impact factor: 7.661

View more
  15 in total

Review 1.  Common errors of drug administration in infants: causes and avoidance.

Authors:  B J Anderson; J F Ellis
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

2.  Paediatric prescribing in out-patient care. An example from Sri Lanka.

Authors:  G Tomson; V Diwan; I Angunawela
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 3.  Fetal drug metabolism and its possible clinical implications.

Authors:  B Krauer; P Dayer
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

Review 4.  Principles of drug biodisposition in the neonate. A critical evaluation of the pharmacokinetic-pharmacodynamic interface (Part II).

Authors:  J B Besunder; M D Reed; J L Blumer
Journal:  Clin Pharmacokinet       Date:  1988-05       Impact factor: 6.447

5.  Anticonvulsants in the newborn period.

Authors:  N Buchanan
Journal:  Indian J Pediatr       Date:  1985 Sep-Oct       Impact factor: 1.967

6.  Preliminary studies on the disposition of meptazinol in the neonate.

Authors:  R A Franklin; T Frost; P J Robson; M B Jackson
Journal:  Br J Clin Pharmacol       Date:  1981-07       Impact factor: 4.335

7.  Routes of meptazinol conjugation in the neonate.

Authors:  P S Dowell; D M Pierce; R A Franklin; P J Robson; M B Jackson
Journal:  Br J Clin Pharmacol       Date:  1982-11       Impact factor: 4.335

Review 8.  Ontogeny of hepatic and renal systemic clearance pathways in infants: part I.

Authors:  Jane Alcorn; Patrick J McNamara
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

9.  Metabolism of 17alpha-hydroxyprogesterone caproate, an agent for preventing preterm birth, by fetal hepatocytes.

Authors:  Shringi Sharma; Ewa C S Ellis; Kenneth Dorko; Shimin Zhang; Donald R Mattison; Steve N Caritis; Raman Venkataramanan; Stephen C Strom
Journal:  Drug Metab Dispos       Date:  2010-01-22       Impact factor: 3.922

10.  Hepatobiliary disposition of 17-OHPC and taurocholate in fetal human hepatocytes: a comparison with adult human hepatocytes.

Authors:  Shringi Sharma; Ewa C S Ellis; Roberto Gramignoli; Kenneth Dorko; Veysel Tahan; Marc Hansel; Donald R Mattison; Steve N Caritis; Ronald N Hines; Raman Venkataramanan; Stephen C Strom
Journal:  Drug Metab Dispos       Date:  2012-11-05       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.